Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% on Insider Selling
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) were down 6.8% during trading on Monday after an insider sold shares in the company. The company traded as low as $322.44 and ...
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...
ETF Daily News2d
What is Leerink Partnrs’ Estimate for MDGL Q2 Earnings?
MDGL has been the topic of several other reports. Citigroup upped their price target on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a “buy” rating in a research note on ...
Nasdaq6d
Guru Fundamental Report for MDGL
Below is Validea's guru fundamental report for MADRIGAL PHARMACEUTICALS INC (MDGL). Of the 22 guru strategies we follow, MDGL rates highest using our Contrarian Investor model based on the ...
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture?
Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.
Madrigal price target raised to $405 from $400 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...
We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn
But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders is whether ...
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley
B. Riley upgraded Madrigal Pharmaceuticals (MDGL) to Buy from Neutral with a price target of $422, up from $236. The firm notes the erosion of ...
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due In Q2
Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
Morningstar2d
Madrigal Pharmaceuticals Inc MDGL
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Nasdaq6d
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture?
High-rolling investors have positioned themselves bullish on Madrigal Pharmaceuticals (NASDAQ:MDGL), and it's important for retail traders to take note. \This activity came to our attention today ...